Skip to main content
Journal cover image

Once-yearly zoledronic acid in older men compared with women with recent hip fracture.

Publication ,  Journal Article
Boonen, S; Orwoll, E; Magaziner, J; Colón-Emeric, CS; Adachi, JD; Bucci-Rechtweg, C; Haentjens, P; Kaufman, J-M; Rizzoli, R; Vanderschueren, D ...
Published in: J Am Geriatr Soc
November 2011

OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once- Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study. DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: International multicenter. PARTICIPANTS: Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison). INTERVENTION: Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements. MEASUREMENT: Changes in BMD. RESULTS: Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0%, P = .003, and 3.8%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men. CONCLUSION: Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

November 2011

Volume

59

Issue

11

Start / End Page

2084 / 2090

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • Treatment Outcome
  • Time Factors
  • Prevalence
  • Osteoporosis
  • Male
  • Injections, Intravenous
  • Incidence
  • Imidazoles
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boonen, S., Orwoll, E., Magaziner, J., Colón-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C., … HORIZON Recurrent Fracture Trial, . (2011). Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc, 59(11), 2084–2090. https://doi.org/10.1111/j.1532-5415.2011.03666.x
Boonen, Steven, Eric Orwoll, Jay Magaziner, Cathleen S. Colón-Emeric, Jonathan D. Adachi, Christina Bucci-Rechtweg, Patrick Haentjens, et al. “Once-yearly zoledronic acid in older men compared with women with recent hip fracture.J Am Geriatr Soc 59, no. 11 (November 2011): 2084–90. https://doi.org/10.1111/j.1532-5415.2011.03666.x.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011 Nov;59(11):2084–90.
Boonen, Steven, et al. “Once-yearly zoledronic acid in older men compared with women with recent hip fracture.J Am Geriatr Soc, vol. 59, no. 11, Nov. 2011, pp. 2084–90. Pubmed, doi:10.1111/j.1532-5415.2011.03666.x.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman J-M, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW, HORIZON Recurrent Fracture Trial. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011 Nov;59(11):2084–2090.
Journal cover image

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

November 2011

Volume

59

Issue

11

Start / End Page

2084 / 2090

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • Treatment Outcome
  • Time Factors
  • Prevalence
  • Osteoporosis
  • Male
  • Injections, Intravenous
  • Incidence
  • Imidazoles
  • Humans